JOINT FILING AGREEMENTJoint Filing Agreement • March 26th, 1998 • Abbott Laboratories • Pharmaceutical preparations
In accordance with Rule 13d-1(f) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a Statement on Schedule 13D (including amendments thereto) with respect to the common shares, without par value, of International Murex Technologies Corporation, and further agrees that this Joint Filing Agreement be included as an exhibit to such filings provided that, as contemplated by Section 13d-1(f)(l)(ii), no person shall be responsible for the completeness or accuracy of the information concerning the other persons making the filing, unless such person knows or has reason to believe that such information is inaccurate. This Joint Filing may be executed in any number of counterparts, all of which together shall constitute one and the same instrument.
Abbott Laboratories 100 Abbott Park Road Abbott Park, IllinoisAbbott Laboratories • March 26th, 1998 • Pharmaceutical preparations
AMENDMENT TO RIGHTS PLANRights Plan • March 26th, 1998 • Abbott Laboratories • Pharmaceutical preparations
March 13, 1998 Michael WarrenAbbott Laboratories • March 26th, 1998 • Pharmaceutical preparations
This letter is to confirm our agreement regarding all of the common shares, without par value, (the "Shares") of International Murex Technologies Corporation, a British Columbia corporation (the "Company") held by you. In order to induce Abbott Laboratories, an Illinois corporation ("Buyer") to enter into an Acquisition Agreement, to be dated as of the date hereof between the Company and Buyer (the "Acquisition Agreement"), you hereby agree as follows:
